Pages
Products
- Residual Protein Testing
- Endotoxin Testing
- 5' Capping Efficiency Testing
- Residual DNA Testing
- dsRNA Testing
- eGFP mRNA
- mCherry mRNA
- FLuc mRNA
- Cre mRNA
- hEPO mRNA
- 5MG Encapsulation
- 1MG Encapsulation
- 500UG Encapsulation
- OVA mRNA
- OVA mRNA Quantity
- hEPO mRNA Quantity
- Cre mRNA Quantity
- FLuc mRNA Quantity
- mCherry mRNA Quantity
- eGFP mRNA Quantity
Posts by category
- Category: Case Study
- Category: News & Insights
- Leveraging mRNA to Revolutionize Antibody Manufacturing
- Harnessing mRNA Quality Insights: Essential Techniques For Rapid Drug Development
- Vernal Appoints Jim Petrilla as CEO and Board Director
- How Analytical Services Drive mRNA & LNP Success
- Vernal Launches Integrated Analytical & QC Services—Facilitating Faster mRNA Medicine Development
- From Data to Decisions: Accelerating Your mRNA Drug Development with Analytics
- CDMO Insights on Therapeutic mRNA
- Democratizing mRNA Technology
- FDA Platform Technology Guidance
- Benefits of Partnering with a US-Based CDMO
- October 2023 Newsletter
- Vernal Showcases Innovations at mRNA Health Conference
- Cas9 mRNA: Gene Editing Advantages
- Vernal Scales Up mRNA Production Successfully
- mRNA Tech Revolutionizes Antibody Engineering
- A Larger Facility
- Vermont Startup Secures $21M for mRNA
- Colchester’s Vernal Biosciences Raises $20 Million to Expand
- Burlington Tech Startup Raises Funds for Growth
- Vernal Biosciences Raises $21M for mRNA Growth
- Vernal Biosciences awarded nearly $100k in Vermont Training Grant
- Vernal to Expand mRNA Team Threefold
- Colchester mRNA lab putting local college grads to work
- Colchester Startup Advances mRNA Applications
- Vernal Biosciences CEO Discusses DNA Utilization
- mRNA in Colchester
- Category: Newsletter
- Category: Press Releases
- Vernal Biosciences Announces Partnership with REPROCELL
- Vernal featured on Businesswire
- Vermont Celebrates Vernal Success in a VT Digger Article
- Vernal Biosciences Featured in Endpoints News
- Vernal Biosciences highlighted in article by Pharma’s Almanac!
- Vernal’s Growth Since 2021
- Vernal Democratizes mRNA Manufacturing Access
- Category: Resources
- The Evolving Needs of Therapeutic mRNA Developers
- The mRNA Monthly—November 2024 Newsletter
- The mRNA Monthly—October 2024 Newsletter
- The mRNA Monthly—September 2024 Newsletter
- The mRNA Monthly—August 2024 Newsletter
- The mRNA Monthly—July 2024 Newsletter
- The mRNA Monthly—June 2024 Newsletter
- The mRNA Monthly—May 2024 Newsletter
- mRNA poly(A) Sizing Methods
- Doggybone™ DNA for In Vitro Transcription
- mRNA Capping Technologies
- Poly(A) Tails For mRNA Synthesis
- April Newsletter
- Anti-SARS-CoV-2 Spike Protein Responses
- Potent Immune Response with Vernal’s LNP-mRNAs
- Vernal’s First Newsletter!
- Formulating LNP-mRNA for Clinical Applications
- Meet Vernal’s Experts at mRNA Health Conference
- Vernal Starts Construction on Vermont mRNA Facility
- Vernal welcomes Scott Vanson and JJ Bivona to the team
- Vernal Launches Preclinical LNP Formulation Service